Mannose-binding lectin and the balance between immune protection and complication

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 12, 2011, Pages 1179-1190

  Takahashi, Kazue ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

coagulation; complement; deficiency; infection; inflammation; mannose binding lectin; MASP; pattern recognition molecules

Indexed keywords

INTERLEUKIN 6; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 1; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 2; MANNOSE BINDING LECTIN; UNCLASSIFIED DRUG;

COMPLEMENT ACTIVATION; COMPLEMENT LECTIN PATHWAY; DISSEMINATED INTRAVASCULAR CLOTTING; GENETIC ASSOCIATION; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; INNATE IMMUNITY; LIVER INJURY; MANNOSE BINDING LECTIN DEFICIENCY; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TISSUE METABOLISM;

ANIMALS; BLOOD COAGULATION; COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; DISEASE SUSCEPTIBILITY; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-6; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; MICE; MICE, KNOCKOUT; OPSONIN PROTEINS; PHAGOCYTOSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 82455184700     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.136     Document Type: Review

References (141)

1. Takahashi K, Ip WE, Michelow IC, Ezekowitz RA. The mannose-binding lectin: a prototypic pattern recognition molecule. Curr. Opin. Immunol. 18(1), 16-23 (2006).
2. Takahashi K, Ezekowitz RA. The role of the mannose-binding lectin in innate immunity. Clin. Infect. Dis. 41(Suppl. 7), S440-S444 (2005).
3. Haurum JS, Thiel S, Haagsman HP, Laursen SB, Larsen B, Jensenius JC. Studies on the carbohydrate-binding characteristics of human pulmonary surfactant-associated protein A and comparison with two other collectins: mannan-binding protein and conglutinin. Biochem. J. 293(Pt 3), 873-878 (1993).
4. Kawasaki T, Etoh R, Yamashina I. Isolation and characterization of a mannan-binding protein from rabbit liver. Biochem. Biophys. Res. Commun. 81(3), 1018-1024 (1978).
5. Estabrook MM, Jack DL, Klein NJ, Jarvis GA. Mannose-binding lectin binds to two major outer membrane proteins, opacity protein and porin, of Neisseria meningitidis. J. Immunol. 172(6), 3784-3792 (2004).
6. Takahashi K, Chang WC, Takahashi M et al. Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology 216(1-2), 96-102 (2011).
7. Chang WC, Hartshorn KL, White MR et al. Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin. Biochem. Pharmacol. 81(3), 388-395 (2011).
8. Krarup A, Wallis R, Presanis JS, Gal P, Sim RB. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2, e623 (2007).
9. Presanis JS, Hajela K, Ambrus G, Gal P, Sim RB. Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol. Immunol. 40(13), 921-929 (2004).
10. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway - its role in innate immunity and evolution. Immunol. Rev. 198, 185-202 (2004).
11. Skjoedt MO, Hummelshoj T, Palarasah Y et al. A novel mannose-binding lectin/ ficolin-associated protein is highly expressed in heart and skeletal muscle tissues and inhibits complement activation. J. Biol. Chem. 285(11), 8234-8243 (2010).
12. Tateishi K, Kanemoto T, Fujita T, Matsushita M. Characterization of the complex between mannose-binding lectin trimer and mannose-binding lectin-associated serine proteases. Microbiol. Immunol. 55(6), 427-433 (2011).
13. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J. Immunol. 161(6), 3169-3175 (1998).
14. Garred P, Madsen HO, Kurtzhals JA et al. Diallelic polymorphism may explain variations of the blood concentration of mannan-binding protein in Eskimos, but not in black Africans. Eur. J. Immunogenet. 19(6), 403-412 (1992).
15. Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency - revisited. Mol. Immunol. 40(2-4), 73-84 (2003).
16. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. Mannose-binding lectin and its genetic variants. Genes Immun. 7(2), 85-94 (2006).
17. Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J. Immunol. Methods 241(1-2), 33-42 (2000).
18. Sumiya M, Super M, Tabona P et al. Molecular basis of opsonic defect in immunodeficient children. Lancet 337(8757), 1569-1570 (1991).
19. Chang WC, White MR, Moyo P et al. Lack of the pattern recognition molecule mannose-binding lectin increases susceptibility to influenza A virus infection. BMC Immunol. 11(1), 64 (2010).
20. Shi L, Takahashi K, Dundee J et al. Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J. Exp. Med. 199(10), 1379-1390 (2004).
21. Moller-Kristensen M, Ip WK, Shi L et al. Deficiency of mannose-binding lectin greatly increases susceptibility to postburn infection with Pseudomonas aeruginosa. J. Immunol. 176(3), 1769-1775 (2006).
22. Gadjeva M, Paludan SR, Thiel S et al. Mannan-binding lectin modulates the response to HSV-2 infection. Clin. Exp. Immunol. 138(2), 304-311 (2004).
23. Muller S, Schaffer T, Flogerzi B et al. Mannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens. Gut 59(11), 1493-1500 (2010).
24. Dhainaut JF, Shorr AF, Macias WL et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit. Care Med. 33(2), 341-348 (2005).
25. Smith EY, Charles LA, Van Cott EM. Biphasic activated partial thromboplastin time waveform and adverse events in non-intensive care unit patients. Am. J. Clin. Pathol. 121(1), 138-141 (2004).
26. Levi M. The coagulant response in sepsis. Clin. Chest Med. 29(4), 627-642, viii (2008).
27. King JE. Sepsis in critical care. Crit. Care Nurs. Clin. North Am. 19(1), 77-86 (2007).
28. Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International society of thrombosis and haemostasis scoring system for disseminated intravascular coagulation. Crit. Care Med. 32(12), 2416-2421 (2004).
29. Ambrus G, Gal P, Kojima M et al. Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments. J. Immunol. 170(3), 1374-1382 (2003).
30. Hajela K, Kojima M, Ambrus G et al. The biological functions of MBL-associated serine proteases (MASPs).Immunobiology 205(4-5), 467-475 (2002).
31. Krarup A, Gulla KC, Gal P, Hajela K, Sim RB. The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochim. Biophys. Acta 1784(9), 1294-1300 (2008).
32. Middleton DB, Zimmerman RK, Mitchell KB. Vaccine schedules and procedures. J. Fam. Pract. 56(2 Suppl. Vaccines), S47-S60, C44-C48 (2007).
33. Kruschinski C, Zidan M, Debertin AS, von Horsten S, Pabst R. Age-dependent development of the splenic marginal zone in human infants is associated with different causes of death. Hum. Pathol. 35(1), 113-121 (2004).
34. Hanson LA, Korotkova M, Lundin S et al. The transfer of immunity from mother to child. Ann. N.Y. Acad. Sci. 987, 199-206 (2003).
35. Newburg DS. Neonatal protection by an innate immune system of human milk consisting of oligosaccharides and glycans. J. Anim. Sci. 87(Suppl. 13), 26-34 (2009).
36. Uemura K, Saka M, Nakagawa T et al. L-MBP is expressed in epithelial cells of mouse small intestine. J. Immunol. 169(12), 6945-6950 (2002).
37. Grasso DL, Segat L, Zocconi E, Radillo O, Trevisiol C, Crovella S. MBL expression in patients with recurrent tonsillitis. Int. J. Pediatr. Otorhinolaryngol. 73(11), 1550-1553 (2009).
38. Bulla R, De Seta F, Radillo O et al. Mannose-binding lectin is produced by vaginal epithelial cells and its level in the vaginal fluid is influenced by progesterone. Mol. Immunol. 48(1-3), 281-286 (2010).
39. Lokitz ML, Zhang W, Bashir M et al. Ultraviolet-B recruits mannose-binding lectin into skin from non-cutaneous sources. J. Invest. Dermatol. 125(1), 166-173 (2005).
40. Fidler KJ, Hilliard TN, Bush A et al. Mannose-binding lectin is present in the infected airway: a possible pulmonary defence mechanism. Thorax 64(2), 150-155 (2009).
41. Yager PH, You Z, Qin T et al. Mannose binding lectin gene deficiency increases susceptibility to traumatic brain injury in mice. J. Cereb. Blood Flow. Metab. 28(5), 1030-1039 (2008).
42. Keshi H, Sakamoto T, Kawai T et al. Identification and characterization of a novel human collectin CL-K1. Microbiol. Immunol. 50(12), 1001-1013 (2006).
43. Degn SE, Jensenius JC, Thiel S. Disease-causing mutations in genes of the complement system. Am. J. Hum. Genet. 88(6), 689-705 (2011).
44. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. Science 284(5418), 1313-1318 (1999).
45. Fraser DA, Tenner AJ. Directing an appropriate immune response: the role of defense collagens and other soluble pattern recognition molecules. Curr. Drug Targets 9(2), 113-122 (2008).
46. Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol. Immunol. 44(16), 3875-3888 (2007).
47. Degn SE, Hansen AG, Steffensen R, Jacobsen C, Jensenius JC, Thiel S. MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J. Immunol. 183(11), 7371-7378 (2009).
48. Dahl MR, Thiel S, Matsushita M et al. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 15(1), 127-135 (2001).
49. Moller-Kristensen M, Thiel S, Sjoholm A, Matsushita M, Jensenius JC. Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway. Int. Immunol. 19(2), 141-149 (2007).
50. Banda NK, Takahashi M, Levitt B et al. Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis. J. Immunol. 185(9), 5598-5606 (2010).
51. Iwaki D, Fujita T. Production and purification of recombinants of mouse MASP-2 and sMAP. J. Endotoxin. Res. 11(1), 47-50 (2005).
52. Takahashi M, Ishida Y, Iwaki D et al. Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J. Exp. Med. 207(1), 29-37 (2010).
53. Wang X, Xu L. An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thromb. Res. 115(1-2), 95-100 (2005).
54. Kretz CA, Vaezzadeh N, Gross PL. Tissue factor and thrombosis models. Arterioscler. Thromb. Vasc. Biol. 30(5), 900-908 (2010).
55. Gulla KC, Gupta K, Krarup A et al. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 129(4), 482-495 (2010).
56. Endo Y, Nakazawa N, Iwaki D, Takahashi M, Matsushita M, Fujita T. Interactions of ficolin and mannose-binding lectin with fibrinogen/fibrin augment the lectin complement pathway. J. Innate. Immun. 2(1), 33-42 (2010).
57. Iwaki D, Kanno K, Takahashi M et al. Small mannose-binding lectin-associated protein plays a regulatory role in the lectin complement pathway. J. Immunol. 177(12), 8626-8632 (2006).
58. Super M, Gillies SD, Foley S et al. Distinct and overlapping functions of allelic forms of human mannose binding protein. Nat. Genet. 2(1), 50-55 (1992).
59. Madsen HO, Garred P, Thiel S et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J. Immunol. 155(6), 3013-3020 (1995).
60. Madsen HO, Garred P, Kurtzhals JA et al. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 40(1), 37-44 (1994).
61. Wallis R. Structural and functional aspects of complement activation by mannose-binding protein. Immunobiology 205(4-5), 433-445 (2002).
62. Lipscombe RJ, Beatty DW, Ganczakowski M et al. Mutations in the human mannose-binding protein gene: frequencies in several population groups. Eur. J. Hum. Genet. 4(1), 13-19 (1996).
63. Collard CD, Shernan SK, Fox AA et al. The MBL2 'LYQA secretor' haplotype is an independent predictor of postoperative myocardial infarction in whites undergoing coronary artery bypass graft surgery. Circulation 116(Suppl. 11), S106-S112 (2007).
64. Matsushita M, Ezekowitz RA, Fujita T. The Gly-54->Asp allelic form of human mannose-binding protein (MBP) fails to bind MBP-associated serine protease. Biochem. J. 311(Pt 3), 1021-1023 (1995).
65. Wallis R, Shaw JM, Uitdehaag J, Chen CB, Torgersen D, Drickamer K. Localization of the serine protease-binding sites in the collagen-like domain of mannose-binding protein: indirect effects of naturally occurring mutations on protease binding and activation. J. Biol. Chem. 279(14), 14065-14073 (2004).
66. Wallis R, Dodd RB. Interaction of mannose-binding protein with associated serine proteases: effects of naturally occurring mutations. J. Biol. Chem. 275(40), 30962-30969 (2000).
67. Brouwer N, Dolman KM, van Zwieten R et al. Mannan-binding lectin (MBL)- mediated opsonization is enhanced by the alternative pathway amplification loop. Mol. Immunol. 43(13), 2051-2060 (2006).
68. Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J. Immunol. 179(6), 4101-4109 (2007).
69. Ganter MT, Brohi K, Cohen MJ et al. Role of the alternative pathway in the early complement activation following major trauma. Shock 28(1), 29-34 (2007).
70. Singh KK, Lieser A, Ruan PK, Fenton T, Spector SA. An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children. J. Aller. Clin. Immunol. 122(1), 173-180 (2008).
71. van der Zwet WC, Catsburg A, van Elburg RM, Savelkoul PH, Vandenbroucke-Grauls CM. Mannose-binding lectin (MBL) genotype in relation to risk of nosocomial infection in pre-term neonates in the neonatal intensive care unit. Clin. Microbiol. Infect. 14(2), 130-135 (2008).
72. Mullighan CG, Heatley SL, Danner S et al. Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. Blood 112(5), 2120-2128 (2008).
73. Tran CT, Kjeldsen K, Haunso S, Hoiby N, Johansen HK, Christiansen M. Mannan-binding lectin is a determinant of survival in infective endocarditis. Clin. Exp. Immunol. 148(1), 101-105 (2007).
74. Faber J, Schuessler T, Finn A et al. Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhood. Ped. Infect. Dis. J. 26(3), 243-246 (2007).
75. Ip WK, Takahashi K, Moore KJ, Stuart LM, Ezekowitz RA. Mannose-binding lectin enhances Toll-like receptors 2 and 6 signaling from the phagosome. J. Exp. Med. 205(1), 169-181 (2008).
76. Takahashi K, Shi L, Gowda LD, Ezekowitz RA. Relative roles of complement factor 3 and mannose-binding lectin in host defense against infection. Infect. Immun. 73(12), 8188-8193 (2005).
77. Super M, Thiel S, Lu J, Levinsky RJ, Turner MW. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 2(8674), 1236-1239 (1989).
78. Gando S, Kameue T, Nanzaki S, Hayakawa T, Nakanishi Y. Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome. Crit. Care Med. 25(11), 1820-1826 (1997).
79. Wada H, Wakita Y, Nakase T et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC study group. Thromb. Haemost. 74(3), 848-852 (1995).
80. Levi M, ten Cate H. Disseminated intravascular coagulation. N. Engl. J. Med. 341(8), 586-592 (1999).
81. Toh CH, Samis J, Downey C et al. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 100(7), 2522-2529 (2002).
82. Downey C, Kazmi R, Toh CH. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Thromb. Haemost. 80(1), 65-69 (1998).
83. Hess JR, Brohi K, Dutton RP et al. The coagulopathy of trauma: a review of mechanisms. J. Trauma. 65(4), 748-754 (2008).
84. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc. Res. 60(1), 26-39 (2003).
85. ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit. Care Med. 28(Suppl. 9), S9-S11 (2000).
86. Ward PA. Role of C5 activation products in sepsis. Sci. World J. 10, 2395-2402 (2010).
87. Chong WP, To YF, Ip WK et al. Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology 42(5), 1037-1045 (2005).
88. Alves Pedroso ML, Boldt AB, Pereira-Ferrari L et al. Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy. Clin. Exp. Immunol. 152(2), 258-264 (2008).
89. Moller-Kristensen M, Hamblin MR, Thiel S, Jensenius JC, Takahashi K. Burn injury reveals altered phenotype in mannan-binding lectin-deficient mice. J. Invest. Dermatol. 127(6), 1524-1531 (2007).
90. Revathi G, Puri J, Jain BK. Bacteriology of burns. Burns 24(4), 347-349 (1998).
91. Song W, Lee KM, Kang HJ, Shin DH, Kim DK. Microbiologic aspects of predominant bacteria isolated from the burn patients in Korea. Burns 27(2), 136-139 (2001).
92. Shankowsky HA, Callioux LS, Tredget EE. North American survey of hydrotherapy in modern burn care. J. Burn Care Rehabil. 15(2), 143-146 (1994).
93. Tredget EE, Shankowsky HA, Rennie R, Burrell RE, Logsetty S. Pseudomonas infections in the thermally injured patient. Burns 30(1), 3-26 (2004).
94. D'Avignon LC, Hogan BK, Murray CK et al. Contribution of bacterial and viral infections to attributable mortality in patients with severe burns: an autopsy series. Burns 36(6), 773-779 (2010).
95. LeVine AM, Hartshorn K, Elliott J, Whitsett J, Korfhagen T. Absence of SP-A modulates innate and adaptive defense responses to pulmonary influenza infection. Am. J. Physiol. Lung Cell Mol. Physiol. 282(3), L563-L572 (2002).
96. LeVine AM, Whitsett JA, Gwozdz JA et al. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J. Immunol. 165(7), 3934-3940 (2000).
97. Li G, Siddiqui J, Hendry M et al. Surfactant protein-A - deficient mice display an exaggerated early inflammatory response to a b-resistant strain of influenza A virus. Am. J. Respir. Cell Mol. Biol. 26(3), 277-282 (2002).
98. LeVine AM, Whitsett JA, Hartshorn KL, Crouch EC, Korfhagen TR. Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J. Immunol. 167(10), 5868-5873 (2001).
99. Yoshida M, Whitsett JA. Alveolar macrophages and emphysema in surfactant protein-D-deficient mice. Respirol. 11(Suppl.), S37-S40 (2006).
100. Stuart LM, Takahashi K, Shi L, Savill J, Ezekowitz RA. Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype. J. Immunol. 174(6), 3220-3226 (2005).
101. Segel MJ, Izbicki G, Cohen PY et al. Role of interferon-g in the evolution of murine bleomycin lung fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 285(6), L1255-L1262 (2003).
102. Konishi A, Aizawa T, Mohan A, Korshunov VA, Berk BC. Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells. J. Biol. Chem. 279(27), 28766-28770 (2004).
103. 2 stress from human diploid fibroblasts. Mol. Cell Proteom. 4(9), 1273-1283 (2005).
104. Shreeniwas R, Koga S, Karakurum M et al. Hypoxia-mediated induction of endothelial cell interleukin-1a. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J. Clin. Invest. 90(6), 2333-2339 (1992).
105. Bhandari V. Developmental differences in the role of interleukins in hyperoxic lung injury in animal models. Front. Biosci. 7, d1624-d1633 (2002).
106. Sin DD, Man SF. Impaired lung function and serum leptin in men and women with normal body weight: a population based study. Thorax 58(8), 695-698 (2003).
107. Jain M, Budinger GR, Lo A et al. Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting peroxisome proliferator-activated receptor-{g}. Am. J. Respir. Crit. Care Med. 183(11), 1490-1498 (2011).
108. Bellmeyer A, Martino JM, Chandel NS, Scott Budinger GR, Dean DA, Mutlu GM. Leptin resistance protects mice from hyperoxia-induced acute lung injury. Am. J. Respir. Crit. Care Med. 175(6), 587-594 (2007).
109. Harijith A, Choo-Wing R, Cataltepe S et al. A role for matrix metalloproteinase 9 in IFN{g}-mediated injury in developing lungs: relevance to bronchopulmonary dysplasia. Am. J. Respir. Cell Mol. Biol. 44(5), 621-630 (2011).
110. Garred P, Pressler T, Madsen HO et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J. Clin. Invest. 104(4), 431-437 (1999).
111. Gong MN, Zhou W, Williams PL, Thompson BT, Pothier L, Christiani DC. Polymorphisms in the mannose binding lectin-2 gene and acute respiratory distress syndrome. Crit. Care Med. 35(1), 48-56 (2007).
112. Carrera MC, Moura P, Crovella S, de Souza PR, de Alencar LC, Sarinho E. High polymorphism of the MBL2 gene in patients with atopic dermatitis. Ann. Allergy Asthma Immunol. 105(1), 39-42 (2010).
113. Hansen TK, Forsblom C, Saraheimo M et al. Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in Type 1 diabetes. Diabetologia 53(7), 1517-1524 (2010).
114. Hansen TK, Gall MA, Tarnow L et al. Mannose-binding lectin and mortality in Type 2 diabetes. Arch. Intern. Med. 166(18), 2007-2013 (2006).
115. Carroll KE, Dean MM, Heatley SL et al. High levels of mannose-binding lectin are associated with poor outcomes after lung transplantation. Transplantation 91(9), 1044-1049 (2011).
116. Bilgin YM, Brand A, Berger SP, Daha MR, Roos A. Mannose-binding lectin is involved in multiple organ dysfunction syndrome after cardiac surgery: effects of blood transfusions. Transfusion 48(4), 601-608 (2008).
117. Trendelenburg M, Theroux P, Stebbins A, Granger C, Armstrong P, Pfisterer M. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur. Heart J. 31(10), 1181-1187 (2010).
118. Lai LT, Lee DC, Ko W, Shevde K, Zhang M. Deficiency of complement factor MBL in a patient required cardiac surgery after an acute myocardial infarction with underlining chronic lymphocytic leukemia. Int. J. Cardiol. 139(2), e24-e26 (2010).
119. Walsh MC, Bourcier T, Takahashi K et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J. Immunol. 175(1), 541-546 (2005).
120. Zhang M, Takahashi K, Alicot EM et al. Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J. Immunol. 177(7), 4727-4734 (2006).
121. Moller-Kristensen M, Wang W, Ruseva M et al. Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand. J. Immunol. 61(5), 426-434 (2005).
122. Esmon CT. Interactions between the innate immune and blood coagulation systems. Trends Immunol. 25(10), 536-542 (2004).
123. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 47(4), 305-314 (2004).
124. Markiewski MM, DeAngelis RA, Lambris JD. Complexity of complement activation in sepsis. J. Cell. Mol. Med. 12(6A), 2245-2254 (2008).
125. van der Poll T, Levi M, Hack CE et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J. Exp. Med. 179(4), 1253-1259 (1994).
126. Newman W, Beall LD, Carson CW et al. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J. Immunol. 150(2), 644-654 (1993).
127. Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit. Care Med. 30(Suppl. 5), S302-S312 (2002).
128. ten Cate H, Schoenmakers SH, Franco R et al. Microvascular coagulopathy and disseminated intravascular coagulation. Crit. Care Med. 29(Suppl. 7), S95-S97; discussion S97-S98 (2001).
129. Yao L, Bengualid V, Lowy FD, Gibbons JJ, Hatcher VB, Berman JW. Internalization of Staphylococcus aureus by endothelial cells induces cytokine gene expression. Infect. Immun. 63(5), 1835-1839 (1995).
130. Collard CD, Montalto MC, Reenstra WR, Buras JA, Stahl GL. Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am. J. Pathol. 159(3), 1045-1054 (2001).
131. Montalto MC, Collard CD, Buras JA et al. A keratin peptide inhibits mannose-binding lectin. J. Immunol. 166(6), 4148-4153 (2001).
132. Massaro M, Scoditti E, Carluccio MA, De Caterina R. Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. Prostaglandins Leukot. Essent. Fatty Acids 79(3-5), 109-115 (2008).
133. Nam NH. Naturally occurring NF-kB inhibitors. Mini. Rev. Med. Chem. 6(8), 945-951 (2006).
134. Megyeri M, Mako V, Beinrohr L et al. Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial function. J. Immunol. 183(5), 3409-3416 (2009).
135. Ohtani K, Suzuki Y, Eda S et al. Molecular cloning of a novel human collectin from liver (CL-L1).J. Biol. Chem. 274(19), 13681-13689 (1999).
136. Ohtani K, Suzuki Y, Eda S et al. The membrane-type collectin CL-P1 is a scavenger receptor on vascular endothelial cells. J. Biol. Chem. 276(47), 44222-44228 (2001).
137. Takahashi K. Ficolins. In: Encyclopedia of Life Sciences. John Wiley & Sons Ltd, Chichester, UK (2008).
138. Gout E, Garlatti V, Smith DF et al. Carbohydrate recognition properties of human ficolins: glycan array screening reveals the sialic acid binding specificity of M-ficolin. J. Biol. Chem. 285(9), 6612-6622 (2010).
139. Petersen KA, Matthiesen F, Agger T et al. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J. Clin. Immunol. 26(5), 465-475 (2006).
140. Michelow IC, Dong M, Mungall BA et al. A novel L-ficolin/mannose-binding lectin chimeric molecule with enhanced activity against Ebola virus. J. Biol. Chem. 285(32), 24729-24739 (2010).
141. Van Till JW, Boermeester MA, Modderman PW et al. Variable mannose-binding lectin expression during postoperative acute-phase response. Surg. Infect. (Larchmt).7(5), 443-452 (2006).